Catalyst Event
ABL Bio Inc (298380) · Other
From Akros SCHK HK-Korea Biotech Index (ASHKBIO)
6/4/2026, 12:00:00 AM
ABL Bio submitted an amended Investigational New Drug (IND) application to Korea's MFDS for its immuno-oncology candidate ABL503 on 2026-06-04. The amendment expands the ongoing Phase 1 trial to include a new monotherapy cohort and a new combination therapy arm with a PD-1 inhibitor.
Korean Translation
2026년 6월 4일, 이중항체 면역항암제 'ABL503'에 대한 임상 1상 시험계획(IND) 변경 신청서를 식품의약품안전처에 제출함. 이번 변경은 새로운 단독요법 코호트 추가 및 PD-1 억제제와의 병용요법 파트 신설을 포함함.
Related Recent Events
Samchundang Pharm Co Ltd (000250) · Other
An extraordinary general meeting of shareholders to appoint a new outside director on June 30, 2026, scheduled. Low impact estimated as the appointment of an outside director is a routine administrative matter.
6/30/2026, 12:00:00 AM
Hansoh Pharmaceutical Group Company Limited (3692) · Other
Annual General Meeting on June 26, 2026, to approve 2025 results and dividends. Analysts estimate a 1-5% price impact for this routine corporate event scheduled.
6/26/2026, 12:00:00 AM
United Laboratories International Holdings Ltd (3933) · Other
The Annual General Meeting is scheduled for June 23, 2026, to vote on financial statements and a potential 20% share issuance mandate which could dilute existing shareholdings; high importance due to potential dilution, scheduled.
6/23/2026, 12:00:00 AM
Aimed Bio Inc (0009K0) · Other
Stock price dropped approximately 18% on June 4, 2026, reportedly due to the expiration of a post-IPO lock-up period, which led to a significant volume of shares being sold by institutional investors.
6/4/2026, 12:00:00 AM
Celltrion Inc (068270) · Trading Issue
Bonus issue of 0.05 new shares per common share. The ex-rights date was June 4, 2026, with the new shares scheduled to be listed on June 30, 2026.
6/4/2026, 12:00:00 AM
Innovent Biologics Inc (1801) · Other
Announcement that CLDN18.2 ADC IBI343 (arcotatug tavatecan) met Phase 3 primary endpoint in gastric cancer and NDA was accepted by NMPA; >10% price impact estimated due to first-in-class status expected
6/4/2026, 12:00:00 AM